CA1297792C - Composition fibrinolytique - Google Patents

Composition fibrinolytique

Info

Publication number: CA1297792C
Authority: CA; Canada
Prior art keywords: c2h4o; approximately; c3h6o; integer; molecular weight
Prior art date: 1986-05-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA000537052A

Other languages

English (en)

Inventor

Robert L. Hunter

Alexander Duncan

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Emory University

Original Assignee

Emory University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-05-15

Filing date

1987-05-13

Publication date

1992-03-24

1987-05-07 Priority claimed from US07/045,459 external-priority patent/US4801452A/en

1987-05-13 Application filed by Emory University filed Critical Emory University

1992-03-24 Application granted granted Critical

1992-03-24 Publication of CA1297792C publication Critical patent/CA1297792C/fr

2009-03-24 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims abstract description 111
239000003527 fibrinolytic agent Substances 0.000 title claims abstract description 61
230000003480 fibrinolytic effect Effects 0.000 title claims abstract description 60
229920001577 copolymer Polymers 0.000 claims abstract description 219
150000001875 compounds Chemical class 0.000 claims abstract description 61
125000000963 oxybis(methylene) group Chemical group [H]C([H])(*)OC([H])([H])* 0.000 claims abstract description 57
208000007536 Thrombosis Diseases 0.000 claims abstract description 37
210000004204 blood vessel Anatomy 0.000 claims abstract description 25
101710196208 Fibrinolytic enzyme Proteins 0.000 claims abstract description 23
108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims abstract description 23
102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims abstract description 23
230000017531 blood circulation Effects 0.000 claims abstract description 21
108010023197 Streptokinase Proteins 0.000 claims abstract description 20
229960005202 streptokinase Drugs 0.000 claims abstract description 19
229960005356 urokinase Drugs 0.000 claims abstract description 19
108090000373 Tissue Plasminogen Activator Proteins 0.000 claims abstract description 16
102000003978 Tissue Plasminogen Activator Human genes 0.000 claims abstract description 16
229960000187 tissue plasminogen activator Drugs 0.000 claims abstract description 16
230000001976 improved effect Effects 0.000 claims abstract description 15
239000000243 solution Substances 0.000 claims description 158
238000000034 method Methods 0.000 claims description 76
210000004369 blood Anatomy 0.000 claims description 64
239000008280 blood Substances 0.000 claims description 64
238000002399 angioplasty Methods 0.000 claims description 43
241001465754 Metazoa Species 0.000 claims description 36
206010028980 Neoplasm Diseases 0.000 claims description 36
102000009123 Fibrin Human genes 0.000 claims description 31
108010073385 Fibrin Proteins 0.000 claims description 31
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 31
229950003499 fibrin Drugs 0.000 claims description 31
239000002516 radical scavenger Substances 0.000 claims description 23
239000001301 oxygen Substances 0.000 claims description 22
229910052760 oxygen Inorganic materials 0.000 claims description 22
239000003146 anticoagulant agent Substances 0.000 claims description 21
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 21
230000010412 perfusion Effects 0.000 claims description 21
210000002216 heart Anatomy 0.000 claims description 20
229940127219 anticoagulant drug Drugs 0.000 claims description 18
210000000056 organ Anatomy 0.000 claims description 18
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 17
102000019197 Superoxide Dismutase Human genes 0.000 claims description 17
108010012715 Superoxide dismutase Proteins 0.000 claims description 17
229960002897 heparin Drugs 0.000 claims description 17
229920000669 heparin Polymers 0.000 claims description 17
239000000082 organ preservation Substances 0.000 claims description 17
230000006378 damage Effects 0.000 claims description 16
208000028867 ischemia Diseases 0.000 claims description 15
230000002934 lysing effect Effects 0.000 claims description 14
230000000302 ischemic effect Effects 0.000 claims description 13
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 12
229930195725 Mannitol Natural products 0.000 claims description 12
235000010355 mannitol Nutrition 0.000 claims description 12
239000000594 mannitol Substances 0.000 claims description 12
208000007056 sickle cell anemia Diseases 0.000 claims description 10
208000010125 myocardial infarction Diseases 0.000 claims description 9
238000002560 therapeutic procedure Methods 0.000 claims description 9
108010073863 saruplase Proteins 0.000 claims description 7
230000000451 tissue damage Effects 0.000 claims description 6
231100000827 tissue damage Toxicity 0.000 claims description 6
239000012266 salt solution Substances 0.000 claims description 5
238000002054 transplantation Methods 0.000 claims description 5
206010003210 Arteriosclerosis Diseases 0.000 claims description 4
208000011775 arteriosclerosis disease Diseases 0.000 claims description 4
238000006213 oxygenation reaction Methods 0.000 claims description 4
239000003153 chemical reaction reagent Substances 0.000 claims description 3
238000004321 preservation Methods 0.000 claims description 3
230000003680 myocardial damage Effects 0.000 claims 10
210000003734 kidney Anatomy 0.000 claims 4
239000003055 low molecular weight heparin Substances 0.000 claims 3
229940127215 low-molecular weight heparin Drugs 0.000 claims 3
238000013171 endarterectomy Methods 0.000 claims 2
229940127090 anticoagulant agent Drugs 0.000 claims 1
239000002246 antineoplastic agent Substances 0.000 claims 1
229940127089 cytotoxic agent Drugs 0.000 claims 1
102000004190 Enzymes Human genes 0.000 abstract description 35
108090000790 Enzymes Proteins 0.000 abstract description 35
229940088598 enzyme Drugs 0.000 abstract description 35
239000007859 condensation product Substances 0.000 abstract description 5
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 abstract description 3
210000001519 tissue Anatomy 0.000 description 29
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 25
230000000694 effects Effects 0.000 description 15
210000001367 artery Anatomy 0.000 description 12
239000011780 sodium chloride Substances 0.000 description 11
238000011282 treatment Methods 0.000 description 11
208000032843 Hemorrhage Diseases 0.000 description 9
210000004351 coronary vessel Anatomy 0.000 description 9
230000009089 cytolysis Effects 0.000 description 9
239000011324 bead Substances 0.000 description 8
238000001802 infusion Methods 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 7
210000004165 myocardium Anatomy 0.000 description 7
229920005862 polyol Polymers 0.000 description 7
150000003077 polyols Chemical class 0.000 description 7
102000008946 Fibrinogen Human genes 0.000 description 6
108010049003 Fibrinogen Proteins 0.000 description 6
229940012952 fibrinogen Drugs 0.000 description 6
210000000440 neutrophil Anatomy 0.000 description 6
108091006146 Channels Proteins 0.000 description 5
230000000747 cardiac effect Effects 0.000 description 5
210000004027 cell Anatomy 0.000 description 5
239000000463 material Substances 0.000 description 5
238000011084 recovery Methods 0.000 description 5
230000010410 reperfusion Effects 0.000 description 5
239000000126 substance Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
229940123457 Free radical scavenger Drugs 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
206010061216 Infarction Diseases 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
230000000903 blocking effect Effects 0.000 description 4
230000001010 compromised effect Effects 0.000 description 4
238000004090 dissolution Methods 0.000 description 4
239000003814 drug Substances 0.000 description 4
230000020764 fibrinolysis Effects 0.000 description 4
230000007574 infarction Effects 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
150000002632 lipids Chemical class 0.000 description 4
230000002107 myocardial effect Effects 0.000 description 4
238000002407 reforming Methods 0.000 description 4
-1 superoxide ions Chemical class 0.000 description 4
230000002195 synergetic effect Effects 0.000 description 4
230000009885 systemic effect Effects 0.000 description 4
230000002885 thrombogenetic effect Effects 0.000 description 4
230000002861 ventricular Effects 0.000 description 4
201000009030 Carcinoma Diseases 0.000 description 3
208000005189 Embolism Diseases 0.000 description 3
206010028851 Necrosis Diseases 0.000 description 3
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 3
208000010378 Pulmonary Embolism Diseases 0.000 description 3
108020004511 Recombinant DNA Proteins 0.000 description 3
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 3
238000007792 addition Methods 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000036770 blood supply Effects 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
230000001186 cumulative effect Effects 0.000 description 3
230000008021 deposition Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
210000005003 heart tissue Anatomy 0.000 description 3
239000012456 homogeneous solution Substances 0.000 description 3
230000004941 influx Effects 0.000 description 3
230000002427 irreversible effect Effects 0.000 description 3
210000003205 muscle Anatomy 0.000 description 3
230000017074 necrotic cell death Effects 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
230000002285 radioactive effect Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
239000008223 sterile water Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
206010011091 Coronary artery thrombosis Diseases 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
206010021143 Hypoxia Diseases 0.000 description 2
206010063837 Reperfusion injury Diseases 0.000 description 2
238000000692 Student's t-test Methods 0.000 description 2
206010054094 Tumour necrosis Diseases 0.000 description 2
239000012190 activator Substances 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000002411 adverse Effects 0.000 description 2
230000004931 aggregating effect Effects 0.000 description 2
238000002583 angiography Methods 0.000 description 2
230000010100 anticoagulation Effects 0.000 description 2
230000003143 atherosclerotic effect Effects 0.000 description 2
230000036765 blood level Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
210000004413 cardiac myocyte Anatomy 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000004087 circulation Effects 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
238000009833 condensation Methods 0.000 description 2
230000005494 condensation Effects 0.000 description 2
230000008602 contraction Effects 0.000 description 2
208000002528 coronary thrombosis Diseases 0.000 description 2
238000004132 cross linking Methods 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
238000002695 general anesthesia Methods 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000023597 hemostasis Effects 0.000 description 2
230000001338 necrotic effect Effects 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
YTSACTNRGUJEGO-UHFFFAOYSA-N oxirane prop-1-ene Chemical group CC=C.C1CO1 YTSACTNRGUJEGO-UHFFFAOYSA-N 0.000 description 2
230000037452 priming Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
230000035488 systolic blood pressure Effects 0.000 description 2
230000002537 thrombolytic effect Effects 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
230000002792 vascular Effects 0.000 description 2
238000005303 weighing Methods 0.000 description 2
208000010444 Acidosis Diseases 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
206010009192 Circulatory collapse Diseases 0.000 description 1
206010069729 Collateral circulation Diseases 0.000 description 1
206010011086 Coronary artery occlusion Diseases 0.000 description 1
101150090997 DLAT gene Proteins 0.000 description 1
206010051055 Deep vein thrombosis Diseases 0.000 description 1
239000004243 E-number Substances 0.000 description 1
235000019227 E-number Nutrition 0.000 description 1
241000490229 Eucephalus Species 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
229940123973 Oxygen scavenger Drugs 0.000 description 1
241000282520 Papio Species 0.000 description 1
102000013566 Plasminogen Human genes 0.000 description 1
108010051456 Plasminogen Proteins 0.000 description 1
241000700159 Rattus Species 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
206010040642 Sickle cell anaemia with crisis Diseases 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 1
206010047249 Venous thrombosis Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000007950 acidosis Effects 0.000 description 1
208000026545 acidosis disease Diseases 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
210000001557 animal structure Anatomy 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
229940125717 barbiturate Drugs 0.000 description 1
HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
239000001045 blue dye Substances 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
229940030602 cardiac therapy drug Drugs 0.000 description 1
239000000496 cardiotonic agent Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000035605 chemotaxis Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
230000034994 death Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
230000003073 embolic effect Effects 0.000 description 1
230000010102 embolization Effects 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
239000012530 fluid Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
210000002064 heart cell Anatomy 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
229940106780 human fibrinogen Drugs 0.000 description 1
230000000544 hyperemic effect Effects 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
230000001146 hypoxic effect Effects 0.000 description 1
229940127121 immunoconjugate Drugs 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011221 initial treatment Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
210000002414 leg Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
239000000693 micelle Substances 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000000178 monomer Substances 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
239000002547 new drug Substances 0.000 description 1
230000000414 obstructive effect Effects 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000036407 pain Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229940043200 pentothal Drugs 0.000 description 1
210000003516 pericardium Anatomy 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
201000003144 pneumothorax Diseases 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
230000008569 process Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
239000008213 purified water Substances 0.000 description 1
239000010453 quartz Substances 0.000 description 1
230000005855 radiation Effects 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
230000004895 regional blood flow Effects 0.000 description 1
238000009877 rendering Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
230000002784 sclerotic effect Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000009528 severe injury Effects 0.000 description 1
206010040560 shock Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
AWLILQARPMWUHA-UHFFFAOYSA-M thiopental sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC([S-])=NC1=O AWLILQARPMWUHA-UHFFFAOYSA-M 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
229960001005 tuberculin Drugs 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/446—Superoxide dismutase (1.15)
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- A61K38/166—Streptokinase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Environmental Sciences (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Dentistry (AREA)
Biomedical Technology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA000537052A 1986-05-15 1987-05-13 Composition fibrinolytique Expired - Lifetime CA1297792C (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US86358286A	1986-05-15	1986-05-15
US863,582		1986-05-15
US07/045,459 US4801452A (en)	1986-05-15	1987-05-07	Fibrinolytic composition
US045,459		1993-04-08

Publications (1)

Publication Number	Publication Date
CA1297792C true CA1297792C (fr)	1992-03-24

Family

ID=26722792

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000537052A Expired - Lifetime CA1297792C (fr)	1986-05-15	1987-05-13	Composition fibrinolytique

Country Status (6)

Country	Link
CA (1)	CA1297792C (fr)
GR (1)	GR870758B (fr)
IE (4)	IE922400L (fr)
NZ (1)	NZ220288A (fr)
PH (1)	PH25909A (fr)
PT (1)	PT84880B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9603966B2 (en)	2007-02-19	2017-03-28	Plurogen Therapeutics, Inc.	Compositions for treating biofilms and methods for using same
US10456416B2 (en)	2015-01-20	2019-10-29	Plurogen Therapeutics, Llc	Compositions and methods of treating microbes

1987
- 1987-05-13 NZ NZ220288A patent/NZ220288A/xx unknown
- 1987-05-13 CA CA000537052A patent/CA1297792C/fr not_active Expired - Lifetime
- 1987-05-14 IE IE922400A patent/IE922400L/xx not_active Application Discontinuation
- 1987-05-14 IE IE922401A patent/IE922401L/xx not_active Application Discontinuation
- 1987-05-14 IE IE922399A patent/IE922399L/xx not_active Application Discontinuation
- 1987-05-14 IE IE126187A patent/IE62088B1/en not_active IP Right Cessation
- 1987-05-15 GR GR870758A patent/GR870758B/el unknown
- 1987-05-15 PH PH35259A patent/PH25909A/en unknown
- 1987-05-15 PT PT84880A patent/PT84880B/pt not_active IP Right Cessation

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9603966B2 (en)	2007-02-19	2017-03-28	Plurogen Therapeutics, Inc.	Compositions for treating biofilms and methods for using same
US9884136B2 (en)	2007-02-19	2018-02-06	Plurogen Therapeutics, Inc.	Compositions for treating biofilms and methods for using same
US10456416B2 (en)	2015-01-20	2019-10-29	Plurogen Therapeutics, Llc	Compositions and methods of treating microbes

Also Published As

Publication number	Publication date
IE922399L (en)	1987-11-15
PT84880B (pt)	1990-02-08
IE871261L (en)	1987-11-15
IE62088B1 (en)	1994-12-14
IE922400L (en)	1987-11-15
NZ220288A (en)	1989-08-29
IE922401L (en)	1987-11-15
PT84880A (en)	1987-06-01
PH25909A (en)	1991-12-19
GR870758B (en)	1988-05-24

Legal Events

Date	Code	Title	Description
2005-03-24	MKLA	Lapsed

Publication	Publication Date	Title
US5089260A (en)	1992-02-18	Method of treating ischemic tissue
US4801452A (en)	1989-01-31	Fibrinolytic composition
US5017370A (en)	1991-05-21	Improved method of performing angioplasty procedures
EP0266419B1 (fr)	1994-03-02	Composition fibrinolytique
US5047236A (en)	1991-09-10	Method of treating stroke
US5028599A (en)	1991-07-02	Method of treating mycardial damage
US5080894A (en)	1992-01-14	Method and composition for reducing tissue damage
US5078995A (en)	1992-01-07	Fibrionolytic composition
US5064643A (en)	1991-11-12	Method for treating sickle cell disease
US4837014A (en)	1989-06-06	An improved method of treating sickle cell anemia
US4873083A (en)	1989-10-10	Fibrinolytic composition
US4879109A (en)	1989-11-07	Method for treating burns
US5030448A (en)	1991-07-09	Method of delivering drugs to damaged or diseased tissue
US5071649A (en)	1991-12-10	Method of preventing blockage in catheters
US5039520A (en)	1991-08-13	Plasma extender
US5041288A (en)	1991-08-20	Method of treating tissue damaged by reperfusion injury
US4897263A (en)	1990-01-30	Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US4937070A (en)	1990-06-26	Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US5032394A (en)	1991-07-16	Method of treating burns
US5182106A (en)	1993-01-26	Method for treating hypothermia
US5250294A (en)	1993-10-05	Improved perfusion medium for transplantation of organs
US5648071A (en)	1997-07-15	Method of treating tumors
US5198211A (en)	1993-03-30	Method of treating myocardial damage
US5240702A (en)	1993-08-31	Method of treating stroke
US5240701A (en)	1993-08-31	Method of performing angioplasty procedures